https://doi.org/10.55788/4673120b
The multicentre, randomised, non-inferiority ALTAR trial (ISRCTN70219762) included 240 women with recurrent UTIs to compare the effectiveness of antibiotic prophylaxis (n=120) with that of methenamine hippurate (n=120). The primary outcome was the incidence of self-reported symptomatic antibiotic-treated UTIs during the 12-month treatment period, with a non-inferiority margin of 1 UTI episode per year.
Methenamine hippurate demonstrated non-inferiority to antibiotic prophylaxis, with incidence rates of 1.38 (95% CI 1.05–1.72) and 0.89 (95% CI 0.65–1.12), respectively. Prof. Christopher Harding (Newcastle University, UK) added that only 52% of the antibiotic-treated UTIs were confirmed by a positive culture, indicating that relying on microbiological cultures only would result in missing almost half of the UTIs. Next, patients in the antibiotic prophylaxis arm displayed a trend towards a higher resistance to at least one antibiotic in E. coli during the 12-month treatment period compared with the patients in the non-antibiotic treatment arm (P=0.052).
Prof. Harding concluded that the results of the ALTAR trial show that methenamine hippurate is an effective alternative to antibiotic preventative treatments in women with recurrent UTIs and that this agent should be considered a novel first-line standard of care.
- Harding C, et al. Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open label, randomised, non-inferiority trial. Game-changing session 4, EAU 2022, 01–04 July.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Letter from the Editor Next Article
Mini-slings non-inferior to standard mid-urethral slings in SUI »
« Letter from the Editor Next Article
Mini-slings non-inferior to standard mid-urethral slings in SUI »
Table of Contents: EAU 2022
Featured articles
Darolutamide performs well across subgroups in mHSPC
Genitourinary Cancer
Does systematic biopsy add value to the detection rate of prostate cancer?
PSMA PET/CT cannot replace mpMRI for diagnosis of prostate cancer
Prostate cancer treatments reduce quality of life
PROpel: Good results for abiraterone plus olaparib in mCRPC
Neoadjuvant hormonal therapy promising in high-risk prostate cancer
Darolutamide performs well across subgroups in mHSPC
Shorter hospital stay with robotic surgery versus open surgery in bladder cancer
Improved risk stratification for high-risk NMIBC
Adjuvant atezolizumab may benefit ctDNA-positive patients with post-op muscle-invasive urothelial carcinoma
New prognostication in N3 penile cancer
KEYNOTE-564: Updated results of adjuvant pembrolizumab in RCC
Fewer complications with robotic surgery in renal cancer
Functional Urology
Novel therapeutic targets for benign prostatic hyperplasia
Mini-slings non-inferior to standard mid-urethral slings in SUI
Non-inferiority of methenamine hippurate to antibiotics in recurrent UTIs
Related Articles
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy